BTIG analyst Ryan Zimmerman has maintained their bullish stance on HUMA stock, giving a Buy rating on April 9.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ryan Zimmerman has given his Buy rating due to a combination of factors including Humacyte’s recent launch of Symvess and its promising market penetration. Since its introduction, approximately 36 hospitals have started the Value Analysis Committee process, with three already approving Symvess for purchase. This early traction suggests that Humacyte could meet or slightly exceed current market expectations for FY25, which anticipates the sale of around 286 units over ten months.
Zimmerman also notes that the company’s revenue projections appear achievable, with the Street estimating $8.44 million for FY25 and a significant increase in FY26. The valuation is supported by a discounted sales analysis, projecting sales out to 2030, and using a 2.5x EV/Sales multiple, which is slightly lower than peers in the regenerative medical technology sector. These factors collectively underpin Zimmerman’s confidence in Humacyte’s growth potential, justifying the Buy rating.
According to TipRanks, Zimmerman is an analyst with an average return of -4.1% and a 39.88% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Globus Medical, GE Healthcare Technologies Inc, and Zimmer Biomet Holdings.
In another report released on April 9, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.